(2001) World Health Report 2001 Mental Health: New Understanding, New Hope, , World Health Organisation. Geneva. World Health Organization
Kessler, R.C., McGonagle, K.A., Zhao, S., Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey (1994) Arch Gen Psychiatry, 51, pp. 8-19
Pitchot, W., Dierick, M., D'Haenen, H., Troubles affectifs (2003) Manuel de Psychopharmacologie, pp. 169-229. , Dierick M, Ansseau M, D'Haenen H, Peuskens J, Linkowski P (Eds). Gent Academia Press
Keller, M., Remission versus response: The new gold standard of antidepressant care (2004) J Clin Psychiatry, 65, pp. 53-59
Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression (2006) N Engl J Med, 354, pp. 1231-1242
Nelson, J.C., Papakostas, G.I., Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials (2009) Am J Psychiatry, 166, pp. 980-991
Weisler, R., Joyce, M., McGill, L., Extended release quetiapine fumarate monotherapy for major depressive disorder: Results of a double-blind, randomized, placebo-controlled study (2009) CNS Spectr, 14, pp. 299-313
McIntyre, R.S., Muzina, D.J., Adams, A., Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: A review of registration trials (2009) Expert Opin Pharmacother, 10, pp. 3061-3075
El-Khalili, N., Joyce, M., Atkinson, S., Extendedrelease quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multicentre, randomized, double-blind, placebo-controlled study (2010) Int J Neuropsychopharmacol, 23, pp. 1-16
Berman, R.M., Fava, M., Thase, M.E., Aripiprazole augmentation in major depressive disorder: A doubleblind, placebo-controlled study in patients with inadequate response to antidepressants (2009) CNS Spectr, 14, pp. 197-206
Nelson, J.C., Thase, M.E., Trivedi, M.H., Safety and tolerability of adjunctive aripiprazole in major depressive disorder: A Pooled post hoc analysis (studies CN138-139 and CN138-163) (2009) Prim Care Companion J Clin Psychiatry, 11, pp. 344-352
Nelson, J.C., Mankoski, R., Baker, R.A., Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: A post-hoc, pooled analysis of two large, placebo-controlled studies (2010) J Affect Disord, 120, pp. 133-140
Trivedi, M.H., Thase, M.E., Osuntokun, O., An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression (2009) J Clin Psychiatry, 70, pp. 387-396
Corya, S.A., Andersen, S.W., Detke, H.C., Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: A 76-week open-label study (2003) J Clin Psychiatry, 64, pp. 1349-1356
Keitner, G.I., Garlow, S.J., Ryan, C.E., A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression (2009) J Psychiatr Res, 43, pp. 205-214
Alexopoulos, G.S., Canuso, C.M., Gharabawi, G.M., Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression (2008) Am J Geriatr Psychiatry, 16, pp. 21-30
Blier, P., Blondeau, C., Neurobiological basis and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder (2011) J Affect Disord, 128 (SUPPL. 1), pp. 3-10
